Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Saghatchian, M.
Right arrow Articles by Théodore, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saghatchian, M.
Right arrow Articles by Théodore, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:535-540, 2001
© 2001 European Society for Medical Oncology

research-article

Carcinoma of an unknown primary site: A chemotherapy strategy based on histological differentiation - results of a prospective study

M. Saghatchian, K. Fizazi, C. Borel, M. Ducreux, P. Ruffié, T. Le Chevalier and C. Théodore

Institut Gustave Roussy Villejuif, France

Correspondence to: M Saghatchian, MD, Service de cancérologie, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France, E-mail mahasti_s{at}yahoo.com

Background To evaluate the efficacy and toxicity of a chemotherapy strategy based on histological differentiation, for patients with carcinoma of unknown primary site

Patients and methods Forty-eight patients were prospectively included in the trial Thirty patients with poorly-differentiated carcinoma or poorly-differentiated adenocarcinoma (group A) received a combination of cisplatin and etoposide Patients with a responsive or stable disease after two cycles received the same regimen plus bleomycin, Ifosfamide and G-CSF Eighteen patients with well- or moderately-differentiated carcinoma (group B) received cisplatin, continuous infusion 5-fluorouracil (5-FU) and {alpha}-interferon. Treatment was maintained in case of response or stable disease for up to six cycles

Results The overall response rate (RR) for the entire group is 43% (95% confidence interval (CI) 35 9%–50 1%). seven CR and five PR in group A (RR = 40%) and six CR and two PR in group B (RR = 44%) Grade 4 leucopenia was observed in 22 (46%) patients and sepsis in 3 (6%) Median survival is 9 4 months (range 5–13 7 months) and 16 1 months (range 11 8–20 3 months), respectively

Conclusions This chemotherapy strategy is one way to achieve high response rates, particularly for patients with well- or moderately-differentiated adenocarcinoma usually considered poorly chemosensitive

cisplatin, continuous infusion 5-FU, etoposide, histological differentiation, unknown primary carcinoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. Culine, A. Kramar, M. Saghatchian, R. Bugat, T. Lesimple, A. Lortholary, Y. Merrouche, A. Laplanche, and K. Fizazi
Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary Site
J. Clin. Oncol., December 15, 2002; 20(24): 4679 - 4683.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.